Merck Regroups On Mevacor Switch; Could CUSTOM Analysis Pave The Way?
This article was originally published in The Tan Sheet
Executive Summary
J&J/Merck is still pursuing an Rx-to-OTC switch of a 20 mg dose of the cholesterol-lowering therapy Mevacor (lovastatin), according to VP-Global Regulatory & Scientific Affairs Edwin Hemwall, PhD
You may also be interested in...
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
Merck’s Mevacor Switch Bid Digs Deeper Into Consumers’ Self-Selection
Merck's self-selection study developed to support its latest Mevacor OTC switch application will bolster its bid by providing deeper insight into consumers' selection decisions, the firm says